作者
Divyanshu Dubey, William S David, Anthony A Amato, Kerry L Reynolds, Nathan F Clement, Donald F Chute, Justine V Cohen, Donald P Lawrence, Meghan J Mooradian, Ryan J Sullivan, Amanda C Guidon
发表日期
2019/9/10
期刊
Neurology
卷号
93
期号
11
页码范围
e1093-e1103
出版商
Lippincott Williams & Wilkins
简介
Objective
To describe the spectrum, clinical course, and management of neuropathies associated with immune checkpoint inhibitors (ICIs).
Methods
Patients with ICI-related neuropathy (irNeuropathy) were identified and their clinical characteristics compared to neuropathy attributed to cytotoxic agents.
Results
We identified 19 patients with irNeuropathies. ICIs included anti-programmed death–1 (PD1), 9; anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA4), 2; and combination of anti-CTLA4 and anti-PD1, 8. Median number of ICI doses prior to neuropathy onset was 4. Rate of neuropathies following ICI therapy was 0.7%. Underlying malignancies included melanoma (n = 15), lung adenocarcinoma (n = 3), and cholangiocarcinoma (n = 1). Neuropathy phenotypes were cranial neuropathies with or without meningitis (n = 7), nonlength-dependent polyradiculoneuropathies with and without cranial nerve …
学术搜索中的文章
D Dubey, WS David, AA Amato, KL Reynolds… - Neurology, 2019